A recent review of the data from 2 major clinical trials shows that PSA screening for prostate cancer does in fact reduce mortality.
You can read the full article, “PSA screening Lowers Mortality, Analysis of Clinical Trials Concludes,” here.
The two clinical trials reviewed were the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO.) Oddly enough, this review, “Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC & PLCO Trials,” looked at the same data as the US Prevention Services Task Force when they issued their recommendation against screening. In light of these recent findings, the authors of this review suggested that perhaps the current recommendations against PSA-based screening need to be revised. The overall findings for the review saw anywhere from 25-32% lower risk of prostate cancer mortality in screened patients from the 2 clinical trials, when compared to no screening.